Key result
Mibefradil significantly reduced diastolic and systolic blood pressure compared to placebo (P<.01), with a significant dose-response relationship (P<.001).
Why the study?
Does mibefradil reduce blood pressure in patients with mild to moderate hypertension?
Population
202 eligible patients with mild to moderate hypertension
Comparison
Mibefradil 25, 50, 100, or 150 mg once a day for… vs Placebo once a day for 4 weeks
Design
RCT, randomized, double-blind, placebo-controlled
Follow-up
4 weeks
Authors
Loading...
Supports mibefradil (25-100 mg daily) for mild-moderate hypertension; confirms dose-dependent efficacy in RCT.
RCT (n=202)
Double-blind
parallel group
Yes
Does mibefradil reduce blood pressure in patients with mild to moderate hypertension?
p-value: p=<.01
Mibefradil is an effective and well-tolerated antihypertensive compound at doses of 25 to 100 mg once daily, providing significant blood pressure reduction with a favorable trough-peak ratio.
Bernink et al. (1996) conducted an RCT in mild to moderate hypertension (n=202). mibefradil vs. placebo was evaluated on drop in blood pressure (diastolic and systolic) (p=<.01). Mibefradil significantly reduced diastolic and systolic blood pressure compared to placebo (P<.01), with a significant dose-response relationship (P<.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: